OncoGenex Pharmaceuticals Inc.NASDAQ
Thu, Nov. 17, 4:38 PM
- OncoGenex Pharmaceuticals (NASDAQ:OGXI) intends to eliminate five additional positions by year end with the aim of saving ~$750K in annual expenses. It announced the first round of cuts in February.
- Previously: OncoGenex tightens belt by cutting 27% of workforce (Feb. 4)
Thu, Nov. 10, 4:35 PM
Thu, Oct. 13, 9:56 AM
- Thinly traded nano cap OncoGenex (OGXI -6.3%) eases in early trading after reporting failed results from a Phase 3 clinical trial, ENSPIRIT, assessing lead product candidate custirsen, in combination with the chemo agent docetaxel, in patients with advanced non-small cell lung cancer (NSCLC) who had progressed after initial chemotherapy. The combination failed to demonstrate a statistically valid increase in median overall survival (OS) compared to docetaxel alone (9.0 months vs. 7.9 months; p=0.178).
- Two months ago, shares plummeted after the company reported failed results in another late-stage trial in treatment-resistant prostate cancer. The company is currently exploring strategic alternatives.
- Previously: OncoGenex's custirsen flunks late-stage study in prostate cancer; shares slump 34% premarket (Aug. 16)
Tue, Aug. 16, 8:03 AM
- Thinly traded nano cap OncoGenex (NASDAQ:OGXI) is down 34% premarket on light volume in response to its announcement that its Phase 3 clinical trial, AFFINITY, assessing lead product candidate custirsen, in combination with cabazitaxel/prednisone, for the treatment of metastatic castration-resistant prostate cancer that has progressed after treatment with docetaxel failed to achieve its primary endpoint of a statistically valid improvement in overall survival (OS) compared to cabazitaxel/prednisone alone.
- Complete data will be presented the the European Society for Medical Oncology (ESMO) Annual Congress in Copenhagen in early October.
- With the aim of conserving resources, the company plans to contact the FDA to discuss its options for an early analysis of the Phase 3 ENSPIRIT study assessing custirsen, in combination with docetaxel, for the second-line treatment of patients with non-small cell lung cancer. It believes that there are a sufficient number of events to demonstrate efficacy since enrollment is almost completed.
- Custirsen blocks the production of the protein clusterin, which is believed to play a key role in cancer cell survival and treatment resistance.
- OncoGenex has engaged MTS Health Partners, LP to assist in exploring strategic alternatives.
Thu, Aug. 4, 4:24 PM
Fri, Jun. 3, 7:37 AM
- Bayer (OTCPK:BAYRY) and Espoo, Finland-based Orion expand their 2014 agreement to jointly develop BAY-1841788 (ODM-201) in prostate cancer, currently in Phase 3 development (ARAMIS study) for the treatment of high-risk non-metastatic castration-resistant prostate cancer.
- The new indication will be for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer, in combination with docetaxel, in men who are starting first-line hormone therapy.
- A Phase 3 study, called ARASENS, will begin enrolling patients in late Q4. The double-blind, placebo-controlled trial will randomize ~1,300 subjects 1:1 to receive either BAY-1841788 (ODM-201) or placebo in combination with an androgen deprivation therapy of the investigator's choice started no more than 12 weeks before randomization. The primary endpoint is overall survival.
- BAY-1841788 is an oral androgen receptor antagonist.
- Prostate cancer-related tickers: (NASDAQ:MDVN)(OTCPK:ALPMY)(NYSE:VRX)(NASDAQ:TTHI)(NASDAQ:EDAP)(NASDAQ:TKAI)(NYSE:JNJ)(NASDAQ:TSRO)(NYSE:AZN)(NASDAQ:EGRX)(NASDAQ:OGXI)
Thu, May 12, 4:05 PM
- OncoGenex Pharmaceuticals (NASDAQ:OGXI): Q1 EPS of -$0.12 in-line.
- Revenue of $2.9M (+111.7% Y/Y) misses by $1.19M.
Wed, Apr. 27, 12:46 PM
Wed, Apr. 27, 9:11 AM
Tue, Apr. 26, 12:46 PM
Tue, Apr. 26, 9:16 AM
Wed, Mar. 9, 4:04 PM
- OncoGenex Pharmaceuticals (NASDAQ:OGXI): Q4 EPS of -$0.06 beats by $0.09.
- Revenue of $6.02M (+6.5% Y/Y) misses by $1.67M.
Thu, Feb. 4, 5:14 PM
- With the aim of extending its cash runway into Q3 2017, nano cap OncoGenex (NASDAQ:OGXI) will cut 27% of its workforce and certain planned expenditures. Its quick assets of ~$55M will be focused on the continued clinical development of Phase 3-stage custirsen and Phase 2-stage apatorsen.
- Previously: OncoGenex's apatorsen flunks mid-stage lung cancer study; shares drop 24% after hours (Jan. 20)
- Previously: OncoGenex's late-stage study of custirsen in prostate cancer to continue as planned; separate analysis shows no improvement in OS in men with poor prognoses; shares down 29% after hours (Dec. 1, 2015)
Wed, Jan. 20, 4:38 PM
- A Phase 2 clinical trial, called Spruce, assessing OncoGenex Pharmaceuticals' (NASDAQ:OGXI) apatorsen (OGX-427), in combination with carboplatin and pemetrexed, in treatment-naive patients with metastatic non-small cell lung cancer (NSCLC) failed to achieve its primary efficacy endpoint, a statistically significant improvement in progression-free survival (PFS) versus placebo.
- The study is ongoing, with overall survival (OS) results expected in H2. Another Phase 2 study in bladder cancer should be completed this summer.
- Apatorsen is a once-weekly intravenous drug designed to inhibit heat shock protein 27 (Hsp27), an intracellular protein that helps cancer cells survive.
- Shares are down 24% after hours on increased volume.
Thu, Jan. 7, 4:24 PM
- In a regulatory filing, OncoGenex Pharmaceuticals (NASDAQ:OGXI) discloses that Ionis Pharmaceuticals (NASDAQ:IONS) has filed a lawsuit against its subsidiary OncoGenex Technologies seeking a portion of $23.2M it received from Teva Pharmaceutical Industries (NYSE:TEVA) for advance reimbursement of R&D expenses related to the termination of collaboration agreement.
- Ionis asserts that OncoGenex is in breach of a July 2008 license agreement that entitled it to a share of certain forms of non-royalty revenue received by OncoGenex. OncoGenex says Ionis is not entitled to a share of monies received for R&D reimbursement, however. Ionis seeks damages and a declaratory judgement.
- As expected, OncoGenex intends to vigorously defend itself in the matter.
Dec. 9, 2015, 9:16 AM